

Singapore Healthcare Management 2019

Tay Bo Hong, Shayne Lin Tingxuan, Celine Tan Xue Lin SingHealth Investigational Medicine Unit

BACKGROUND

- > From 2017 to 2018, there were several cases of near misses and inaccurate information on drug labels received from vendors/sponsors at SingHealth Investigational Medicine Unit for clinical trial research.
- > These errors were only identified prior to drug administration which causes 'Near misses' in drug administration.
- > If these errors were not captured in time before administration, it could lead to serious consequences affecting patient safety.
- > Thus, to prevent medication errors before drug administration, we created the "RDA" Quality Control checklist as a simple and effective way to conduct checks during the medication handling process.

AIMS

Eliminate errors and near misses prior to medication administration

Ensure information on drug labels are correct and sufficient in accordance to regulatory requirement

To capture any discrepancy in information when matching research subject's prescriptions with drug label

To protect research subject's safety

METHODOLOGY

Using this system, our staff can easily identify errors on medication labels and prescriptions before they are administered to our research subjects. The system consisted of three sequential checkpoints also known as "RDA". Each checkpoint comprises of Key Performance Indicators that aid the staff during drug handling from receipt to drug administration:



- During drug receipt from sponsor, labels are checked against the Receipt Checklist (Picture 1) for labelling requirements by HSA
- Label errors (e.g. wrong protocol number) can be identified at this checkpoint before proceeding to dispensation


ото	COL NO.:														
UEC	T/ BATCH/ LOT N	IO. (delete accord	ingty):												
TE:			OUAN		OF LABELS:										
		•	-												
Refer to the HSA's labelling requirements Key Performance Indicators (IP Labeling)									Cond	ltions	<u> </u>		FUL	FLUTHE 3 CONDITIO	INS
								not used in the clinical trial in a blinded fashion; and	DO NOT DUE DUE THE 3						
					IPs with INCOMPLETE information		1		not re-packaged for use in the trial; and used in accordance with the terms of its product registration/licence	COND	CONDITIONS		Supply to Subje		
	on the Labels as per HSA's labelling requirements for			ror	on the Labels as per HSA's labelling requirements for		Error	_		Wholesale	Supply to	Wholesale	investigational	Audi	
				fied?			Rectified?			Labelling Gement	Supply	Subject	Supply	Product	
	BUnregistered IP	5			BUnregistered IP: ERegistered IPs				а		X	4	X	1	
	ERegistered IPs				exegistered ins				ь	a clinical trial reference code allowing identification of the trial, site, investigator and	×	<i>*</i> •	×	1	
e n	PRIMARY	SECONDARY			PRIMARY LABELS	SECONDARY LABELS	Yes			sponsor; the trial subject identification number or treatment number and, where relevant, visit	x	1.	NA	NA	N
5	LABELS	LABELS	Yes	No				No	•	number; the name of the person to whom the product is to be administered or the trial subject					-
-									d	identification number;	NA	NA	×	1	
										the name, address and telephone number of the main contact for -	x	1.	NA.	NA	T
,										 Information on the product; Information on the trial; and 					
_							<u> </u>			(iii) emergency unblinding;					
:										the name, address and any identification number or logo of the licensed healthcare	NA	NA	×	4	Г
1									'	Institution, licensed retail pharmacy, or trial site where the product is supplied or dispensed:					
							<u> </u>			the name of the substance used in the product and its strength or potency, as well as, in	1	1	NA	NA	T
									8	the case of blinded trials, the name of the comparator or placebo;					
										the name of the product, being the appropriate non- proprietary name and the	NA	NA	1	4	Γ
_							<u> </u>			proprietary designation; the pharmaceutical form, route of administration and quantity of docage units of the	1.	1.	NA	NA	+
5									1	product;					
									1	where the appropriate non-proprietary name is included on the label of the product, the appropriate quantitative particulars of any active ingredient of the product;	NA	NA	1	4	Г
							<u> </u>			the appropriate quantitative particulars of any active ingredient of the product; the directions for use of the product (which may be a reference to a leaflet or other	×	1.	x		⊢
									k	explanatory document intended for use by the subject or person administering the					
										product); the batch or code number identifying the contents and packaging operation of the	1.	1.	NA	NA	+
_							<u> </u>		1	product;					
:									m		NA	NA	4	4	
1										the period of use (which may be an expiry date or a retest date) in month and year format and in a manner that avoids any confusion as to which is the month and which	<i>*</i> •	4.	NA	NA	
							<u> </u>			format and in a manner that avoids any confusion as to which is the month and which is the year.					
١									0		NA	NA	1	4	
•									P			-	NA	NA	
									9	where the product is registered/approved, the registration number/ product licence	NA	NA NA	×		-
)							<u> </u>		, r	number assigned to the product by the Authority.			· ·		
•									* Eleme	nt(s) need not appear on the label if it is available by any other means, so long as the pr	ndples of label	ing are compile	ed with and rea	sions for	
1									omissio	n are set out in the Reasons for Labelling Omissions Form (see Appendix B in HSA_CTB	Guidance_Lab	elling_MP_TP	_31Jan2018.pd	10	
r i							1								




- *If there are errors on* the label, do not proceed to 2nd checkpoint.
- Error must be rectified *before proceeding.*



- Drugs and requisites (for IV infusion for chemotherapy) will be verified against the prescription for dispensation of drugs using the Dispensation Checklist (Picture 2)
- Drugs that are expired can be captured and isolated at this checkpoint



Picture 2: Sample of Dispensation Checklist





If there are errors when verifying drugs with prescription, do not proceed to last checkpoint.

Error must be rectified before proceeding.

- Final checkpoint before drug administration to subjects
- Drugs will be checked by research nurses using the Dosing Checklist (Picture 3) to capture any discrepancy in information when matching prescription with drug labels

			DOSING (C	CRN)						
	Key Performance Indicators	Ma	tch IP Orders	with Primary	Labels	Match	IP Orders wit	Remarks		
S/N	(Dosing of IP and AP)		Total Near Misses	Actual Error	Total Actual Errors	Near Miss	Total Near Misses	Actual Error	Total Actual Errors	
1	IP and/or AP with inaccurate / incomplete prescription									
2	IP and/or AP with inaccurate / incomplete label									
3	IP and/or AP with inaccurate requisite/s used									
4	IP and/or AP with incompatible solution used									
5	IP and/or AP with non-adherence to protocol specific requirement for dosing									
6	IP and/or AP with inaccurate dosage administered									
Legend: Incomplete = Lacking some part of the required details Inaccurate = Not in accordance with what is required Note: Refer to IP/AP Tracking Process Guidelines concerning standard requirements for each indicator listed above IP: Investigational Product, is defined as a Therapeutic Product/ Medicinal Product or a placebo that is to be tested or used as a reference in a clinical trial. AP: Auxiliary Product, is defined as a Therapeutic Product/ Medicinal Product used for the needs of a clinical trial as described in the protocol, but not as an investigational product.										
Recorded by (Initials/Date):										
No. of Dosing:										

Picture 3: Sample of Dosing Checklist

RESULT

Ever since the implementation of the "RDA" quality control checklist in December 2018, we have achieved 100% accuracy for drug administration (Picture 4). We hope to achieve and maintain the accuracy by eliminating potential errors that will occur.

corded by (Initials/Date):

Picture 1: Sample of Receipt Checklist

CONCLUSION

The development of various medical treatment and therapy give rise to a wide array of drugs and requisites used in hospitals. Hence, there is a need for a system in place to ensure all the drugs, instruments and medical requisites used are correct. The introduction of this "RDA" Quality Control Checklist acts as an effective control measure to target and reduce errors during medication administration to ensure patient's safety. This measure has been implemented at SingHealth Investigational Medicine Unit and used actively for clinical trials.



Picture 4: Data Collected from Dec 18 to Apr 19